Smoking cessation treatment for schizophrenia patients using varenicline

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to evaluate the feasibility of using varenicline to assist smoking cessation in patients with schizophrenia or schizoaffective disorder who are experiencing tardive dyskinesia due to antipsychotic medications. Over a 12-week period, 10 participants will undergo a smoking cessation program after a 2-week baseline assessment. The study will monitor changes in smoking status and neurological symptoms using standardized rating scales to determine if varenicline can reduce antipsychotic-induced neurological side effects without exacerbating acute symptoms. The findings may provide insights into the relationship between smoking cessation and neurological symptoms in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* DSM 5 criteria for schizophrenia or schizoaffective disorder and stable disease
* Glazer-Morgenstern-Doucette criteria for TD
* Smoking at least 5 cigarettes on average daily for at least 30 days prior to screening
* An exhaled carbon monoxide concentration greater than 5 parts per million (ppm) at screening
* Agree to stop smoking by the target date (four weeks after baseline
* Concurrence for varenicline treatment from the patient's mental health provider if the patient is under mental health care; OR, if the patient is not under mental health care, the prescribing clinician should consult with a mental health provider to evaluate the patient for appropriateness to receive varenicline

Exclusion Criteria:

* Have untreated or unstable acute medical or psychiatric illnesses
* Have a history of seizures
* History of somnambulism
* Have chronic degenerative neurological illnesses (e.g., Parkinson's disease)
* Have a history of active substance abuse (including marijuana abuse) in the 3 months prior to screening or a positive toxicology screen
* Are receiving clozapine or cholinesterase inhibitors
* Had a change in dosing or medication type of antipsychotic or anti-muscarinic for one month prior to enrollment (two months for long-acting antipsychotics)
* Are unable to remain on a stable dose of antipsychotic or anti-muscarinic during the study period
* Have acute suicidal ideation, intent or behavior within 12 months or risk based assessed on the C-SSRS or depression/anxiety score ≥ 8 on the HADS.
* Female subjects of childbearing age will have a negative pregnancy serum test at screening and are required to use approved methods of birth control
* Use of an investigational drug within 30 days of screening
* Use of other smoking cessation aids (bupropion, nicotine replacement products)
* Use of other tobacco products
* History of allergic reactions to varenicline
* Lack capacity to provide informed consent

Where it's running

• Corporal Michael J Crescenz VA Medical Center
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Stanley N Caroff, MD — Cpl. Michael J. Crescenz VA Medical Center
• Study coordinator: Stanley N Caroff, MD
• Email: stanley.caroff@va.gov
• Phone: 215-823-4065

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor

  This trial will test whether valbenazine reduces involuntary movements in adults with tardive dyskinesia who still have symptoms while taking or after stopping a VMAT2 inhibitor.

  Recruiting at 19 sites Phase 4 Neurocrine Biosciences · Bryant, Arkansas and 18 other locations · NCT07105111

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• State Representation in Early Psychosis 2

  This observational study tests how people with early psychosis and healthy individuals use state information during tasks and how brain activity supports it.

  Recruiting at 2 sites University of Minnesota · Minneapolis, Minnesota and 1 other locations · NCT07834203

• Trying the Kiso Mind smartphone app for people with schizophrenia spectrum disorders

  This study tests whether the Kiso Mind smartphone app is acceptable, practical, and helpful for adults with schizophrenia or schizoaffective disorder alongside their usual care.

  Recruiting Charite University, Berlin, Germany · Berlin, State of Berlin · NCT07395206

• Using AI to Improve Rehabilitation for Patients with Severe Mental Disorders

  This study is testing if using AI and fun games can help people with severe mental disorders improve their social skills and get back into the community.

  Recruiting Shanghai Mental Health Center · Shanghai · NCT06904079

• Enhancing Veteran-Clinician Collaboration in VA Care for Serious Mental Illness

  This study tests a 10-session group program to help Veterans with serious mental illness collaborate better with their clinicians and care teams.

  Recruiting VA Office of Research and Development · San Diego, California and 2 other locations · NCT06898879

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.